Puma Biotechnology, Inc.
General ticker "PBYI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $184.2M (TTM average)
Puma Biotechnology, Inc. follows the US Stock Market performance with the rate: 48.0%.
Estimated limits based on current volatility of 6.5%: low 5.84$, high 6.65$
Factors to consider:
- Total employees count: 172 (-7.0%) as of 2024
- Top business risk factors: Economic downturns and volatility, Public health crises, Cybersecurity threats, Product recalls, Strategic risks and growth management
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.16$, 7.78$]
- 2026-12-31 to 2027-12-31 estimated range: [4.30$, 7.98$]
Financial Metrics affecting the PBYI estimates:
- Positive: with PPE of 8.2 at the end of fiscal year the price was low
- Positive: Operating cash flow per share per price, % of 14.23 > 12.96
- Positive: 7.67 < Operating profit margin, % of 16.33
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 2.25 <= 3.28
- Positive: -14.22 < Investing cash flow per share per price, % of -12.32
Short-term PBYI quotes
Long-term PBYI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $235.64MM | $230.47MM | $228.37MM |
| Operating Expenses | $203.00MM | $199.50MM | $191.07MM |
| Operating Income | $32.64MM | $30.97MM | $37.30MM |
| Non-Operating Income | $-9.97MM | $-6.87MM | $-1.52MM |
| Interest Expense | $13.33MM | $12.45MM | $6.62MM |
| R&D Expense | $50.38MM | $54.94MM | $62.07MM |
| Income(Loss) | $22.67MM | $24.10MM | $35.78MM |
| Taxes | $1.08MM | $-6.18MM | $-1.43MM |
| Profit(Loss)* | $21.59MM | $30.28MM | $31.11MM |
| Stockholders Equity | $53.44MM | $92.12MM | $130.34MM |
| Inventory | $7.08MM | $8.72MM | $5.51MM |
| Assets | $230.53MM | $213.33MM | $216.30MM |
| Operating Cash Flow | $27.01MM | $38.92MM | $41.80MM |
| Capital expenditure | $12.64MM | $0.06MM | $0.07MM |
| Investing Cash Flow | $-19.12MM | $-20.44MM | $-36.19MM |
| Financing Cash Flow | $0.00MM | $-33.85MM | $-45.20MM |
| Earnings Per Share** | $0.46 | $0.62 | $0.62 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.